Scope
The joint AAD–HSF guidance addresses long-term hidradenitis suppurativa, acute flares, procedures and supportive care. These official recommendation highlights distinguish strong biologic recommendations from conditional treatment options and areas with insufficient evidence.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choose medical treatment according to severity
- Adalimumab, bimekizumab, infliximab and secukinumab are strongly recommended for moderate-to-severe hidradenitis suppurativa. [1]
- Topical clindamycin, resorcinol and ruxolitinib are conditional treatment options aimed at reducing abscesses and symptom severity. [1]
- Conditional systemic antibiotic options include doxycycline, tetracycline, clindamycin combined with rifampin, and ertapenem. The highlights describe effects on symptom severity and quality of life but do not give course lengths. [1]
- Oral spironolactone is a conditional hormonal option for reducing disease severity. [1]
- Upadacitinib and short-term systemic corticosteroids are conditional oral options for moderate-to-severe disease, intended to reduce disease activity and pain. [1]
- Continuing adalimumab in patients with moderate-to-severe disease who undergo surgery is included among the conditional recommendations. [1]
Match procedures to the lesion and treatment goal
- Conditional procedural options include deroofing for recurrent or persistently troublesome lesions and incision and drainage for painful abscesses. [1]
- Surgical removal of affected skin is an option for abscesses or tunnels that persist or recur. [1]
- Laser hair removal and botulinum toxin are conditional procedural options to reduce flares. Intralesional triamcinolone is a conditional option for painful, flaring lesions. [1]
Add supportive pain management when needed
- Supportive pain management is conditionally recommended because disease-directed treatment may not provide adequate analgesia. Address acute, persistent and treatment-refractory pain. [1]
- The highlights list warm or cool compresses, topical lidocaine, acetaminophen, NSAIDs, steroid injections, drainage and short-term systemic steroids for acute pain. Opioids are described as an option when other treatments fail to reduce pain, not as the initial default. [1]
- For long-lasting pain, the source lists SNRIs, tricyclic antidepressants, psychotherapy, wound care and neuropathic-pain medicines such as gabapentin and pregabalin. [1]
Respect conditional choices and evidence gaps
- There is insufficient evidence to support oral contraceptive pills or finasteride for hidradenitis suppurativa management. [1]
- Evidence is insufficient for weight reduction or GLP-1 therapy specifically as hidradenitis suppurativa treatment. The same limitation applies to the named disease-specific dietary plans. A heart-healthy diet remains important for cardiovascular and diabetes risk. [1]
- Tobacco cessation is conditionally recommended and may improve the response to disease-directed treatment. [1]
- Vitamin D supplementation for people with deficiency and zinc supplementation are conditional complementary options. Use them under medical supervision; the recommendation for vitamin D is not an endorsement of supplementation regardless of deficiency. [1]
Limitations and use
- The source is the official recommendation highlights release, not the complete guideline. Dosing, detailed eligibility, contraindications, monitoring and all age-specific restrictions are not established here. Conditional options require an individualized benefit–risk discussion. Statements of insufficient evidence do not prove that an intervention is ineffective.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Hidradenitis suppurativa — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAD / HSF
- First published
- 20 October 2026
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.